National Consultant - Paediatric Medicines Landscape Review, Needs Estimation, and Bottleneck Analysis, Indonesia

IMPORTANT NOTICE: Please note that the deadline for receipt of applications indicated above reflects your personal device's system settings.

Purpose of consultancy The purpose of this consultancy will be to conduct a comprehensive national assessment of the paediatric medicines landscape, including needs estimation, bottleneck analysis, and identification of priority paediatric formulations. The consultant will also support national stakeholder engagement and contribute to the development of a national roadmap to improve access to paediatric medicines.

Background

Despite global progress in reducing child mortality, nearly 5 million children under the age of five still die each year, the majority in low- and middle-income countries, including those in Asia. These deaths are often preventable, yet children continue to lack access to medicines that are safe, effective, affordable, and designed specifically for their needs. Many medicines used for children are either unavailable in suitable formulations, not quality-assured, or prescribed without a strong evidence base. This gap in appropriate paediatric medicines undermines progress toward the Sustainable Development Goals (SDGs) and universal health coverage (UHC) targets.
Recognizing these challenges, the World Health Assembly in 2016 and then in 2024 reaffirmed the global commitment to improve children’s health. Member States called for urgent action to accelerate the development, registration, and supply of child-friendly formulations and to strengthen the national and regional systems needed to deliver them.

To meet this call, WHO launched the Global Accelerator for Paediatric Formulations (GAP-f) in 2020, a unique global platform to coordinate stakeholders across the medicine lifecycle — from research and development to regulatory approval and access. GAP-f has already mobilized 33 partner organizations working across multiple therapeutic areas. As GAP-f enters its next strate